Samsaracap

Samsara is a provider of investment and financial advisory services.

Business Model:

Revenue: $0

Employees: 0-0

Rankings

Industries / Tags:

Financial Services

Detailed Samsaracap Information

Geographic Data

Samsaracap headquarters map

Address:

City:

State:

Zip:

Country:

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$310M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Samsara is a provider of investment and financial advisory services.

Contact Phone:

Contact Email:

Samsaracap went public on the NASDAQ

Listed Exchange:
NASDAQ

Ticker Symbol:
JYAC

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
9/2020 Synthekine Series A 82M
4/2021 Mineralys Therapeutics Series A 0
7/2018 Sutro Biopharma Series E 0
1/2021 Genalyte Venture Round 0
9/2022 Autobahn Therapeutics Venture Round 0
5/2019 ElevateBio Series A 150M
2/2021 Viracta Therapeutics Post-IPO Equity 65M
10/2019 MiroBio Series A 33.2M
3/2020 ElevateBio Series B 170M
6/2020 Autobahn Therapeutics Series B 76M
7/2020 Nura Bio Series A 73M
6/2022 Scholar Rock Post-IPO Equity 0
9/2021 Alamar Biosciences Series B 80M
9/2018 Atreca Series C 125M
10/2020 A2 Biotherapeutics Series B 71.5M
7/2020 Alpine Immune Sciences Post-IPO Equity 60M
1/2020 Fluent BioSciences Series A 0
6/2020 Fulcrum Therapeutics Post-IPO Equity 0
2/2022 Seismic Therapeutic Series A 0
6/2022 MiroBio Series B 0
11/2020 Decibel Therapeutics Series D 82.2M
1/2019 Dewpoint Therapeutics Series A 60M
7/2020 Bolt Biotherapeutics Series C 93.5M
6/2020 Mereo Biopharma Post-IPO Equity 0
12/2020 Syros Pharmaceuticals Post-IPO Equity 90.5M
3/2023 CARGO Therapeutics Series A 0
11/2020 Elevation Oncology Series B 65M
5/2021 NiKang Therapeutics Series C 200M
12/2017 Allakos Series B 100M
9/2020 Rain Therapeutics Series B 63M
9/2020 Dewpoint Therapeutics Series B 0
2/2019 Hookipa Pharma Series D 37.4M
1/2022 Simcha Therapeutics Series B 40M
6/2022 Mineralys Therapeutics Series B 0
8/2019 Delfi Diagnostics Seed Round 5.5M
9/2021 Attralus Series B 116M
8/2021 Pepgen Venture Round 0
10/2020 RayzeBio Series A 45M
11/2019 A2 Biotherapeutics Series A 57M
7/2022 Delfi Diagnostics Series B 0
9/2020 Ionpath Series B 0
7/2020 Verona Pharma Private Placement 200M
12/2019 Liquidia Technologies Post-IPO Equity 0
10/2018 Velicept Therapeutics Series B 15M
4/2022 Lyra Therapeutics Post-IPO Equity 0
9/2022 ACELYRIN Series C 0
1/2021 IO Biotech Series B 0
9/2019 Nkarta Therapeutics Series B 114M
2/2021 Notch Therapeutics Series A 85M
10/2022 Enlaza Therapeutics Seed Round 61M
6/2020 Autobahn Labs Seed Round -
4/2019 SpringWorks Therapeutics Series B 125M
1/2021 Abcuro Series A 42M
5/2019 AlloVir Series B 120M
1/2022 Septerna Series A 100M
1/2023 Palvella Therapeutics Series D 37.7M
12/2018 Bellus Health Post-IPO Equity 26M
2/2019 Neurogene Series A 68.5M
4/2021 Janux Therapeutics Series B 0
3/2018 Omniox Series D -
6/2022 ImmunOs Therapeutics Series B 0
11/2021 ACELYRIN Series B 0
3/2021 EGenesis Series C 0
2/2022 Dewpoint Therapeutics Series C 0
10/2020 Primmune Therapeutics Series A 0
3/2021 ElevateBio Series C 525M
5/2023 ElevateBio Series D 0
6/2021 Abata Therapeutics Series A 0
5/2023 OnKure Therapeutics Series C 0
9/2020 Graphite Bio Series A 45M
8/2021 Tango Therapeutics Post-IPO Equity 0
9/2021 Obsidian Therapeutics Series B 0
2/2021 Pipeline Therapeutics Series C 0
10/2021 Tentarix Biotherapeutics Series A 50M
12/2020 RayzeBio Series B 105M
6/2023 Upstream Bio Series B 0
5/2023 Lyra Therapeutics Post-IPO Equity 0
12/2022 Alpha9 Theranostics Series B 0
8/2020 Chinook Therapeutics Private Placement 106M
9/2020 Recursion Pharmaceuticals Series D 239M
9/2020 Eledon Pharmaceuticals Post-IPO Equity 108M
2/2021 Centessa Pharmaceuticals Series A 250M
3/2021 OnKure Series B 56.6M
7/2021 Prime Medicine Series B 200M
9/2021 HilleVax Equity 135M
3/2021 Graphite Bio Series B 150.7M
6/2021 RayzeBio Series C 108M
2/2023 Abivax Post-IPO Equity 0
10/2021 Exo Therapeutics Series B 0
6/2021 Synthekine Series B 0
9/2020 Flame Biosciences Venture Round 100M
7/2020 Cogent Biosciences Post-IPO Equity 104.4M
9/2020 Palladio Biosciences Series B 20M
11/2021 Ablaze Pharmaceuticals Series A 0
6/2022 Upstream Bio Series A 200M
8/2019 Chinook Therapeutics Series A 65M
11/2021 SanReno Therapeutics Funding Round 0
1/2021 Delfi Diagnostics Series A 0
8/2017 Levo Therapeutics Series A -
5/2020 Palvella Therapeutics Series C 0
10/2022 immatics biotechnologies Post-IPO Equity 0
12/2019 FORMA Therapeutics Series D 100M
10/2021 Science 37 Post-IPO Equity 0
5/2021 Vedere Bio ll Series A 0
2/2022 Eyebiotech Series A 0
11/2019 Pieris Pharmaceuticals Post-IPO Equity 0
8/2021 Neurogastrx Series B 60M
7/2022 Delfi Diagnostics Series B 0
6/2022 MiroBio Series B 0
6/2022 Scholar Rock Post-IPO Equity 0
6/2022 Mineralys Therapeutics Series B 0
6/2022 ImmunOs Therapeutics Series B 0
6/2022 Upstream Bio Series A 0
4/2022 Lyra Therapeutics Post-IPO Equity 0
2/2022 Eyebiotech Series A 0
2/2022 Seismic Therapeutic Series A 0
2/2022 Dewpoint Therapeutics Series C 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research
CoBee's Logo
Copyright © CoBee 2022. All Rights Reserved.